P2.06-12 The Safety and Efficacy of Durvalumab as 1st Line Therapy in Patients with Advanced NSCLC and ECOG PS of 2

K. Shaverdashvili,V. Reyes,H. Wang, D. Mehta, C. Marsh, J.K. Waas, R.A. VanderWeele, S.M. Peracha, H. Liang,D.E. Gerber,J. Dowell,L.C. Villaruz

Journal of Thoracic Oncology（2023）

引用 0|浏览2

暂无评分

摘要

Durvalumab remains the only FDA-approved agent for patients with unresectable stage III NSCLC after the completion of definitive chemoradiotherapy. Approximately 30-40% of patients with advanced and metastatic NSCLC present with an ECOG PS of 2. However, there are limited prospective data on the safety and efficacy of durvalumab in NSCLC patients with impaired PS.

查看译文

关键词

durvalumab,1st line therapy,efficacy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要